# EDGAR Filing Document

**Accession Number:** 0001541157
**File Stem:** 0001641172-25-021570
**Filing Date:** 2025-7
**Character Count:** 2520
**Document Hash:** 25516accba8a4d7d647ae30c670596c9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-021570.hdr.sgml**: 20250828

**ACCESSION NUMBER**: 0001641172-25-021570

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250730

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Akari Therapeutics Plc
- **CENTRAL INDEX KEY:** 0001541157
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981034922
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** FL 7
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** (646) 350-0702

**MAIL ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** FL 7
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Celsus Therapeutics Plc.
- **DATE OF NAME CHANGE:** 20130621

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Morria Biopharmaceuticals PLC
- **DATE OF NAME CHANGE:** 20120201

**Akari Therapeutics, PLC**

**22 Boston Wharf Road Fl. 7**

**Boston, MA 02210**

July 30, 2025

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Akari Therapeutics PLC** |
|  | **Registration Statement on Form S-3**<br> **File No. 333-289056** |

---

<u>VIA EDGAR</u>

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akari Therapeutics PLC (the "**Registrant**") hereby respectfully requests that the effectiveness of the Registration Statement on Form S-3 (File No. 333-289056) of the Registrant (the "**Registration Statement**") be accelerated so that the Company's Registration Statement will be declared effective at 5:00 p.m., Eastern Time, on July 31, 2025 or as soon thereafter as may be practicable.

The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Greenberg Traurig, LLP, by calling Win Rutherfurd at (305) 579 0769. The Company hereby authorizes Mr. Rutherfurd to orally modify or withdraw this request for acceleration.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| AKARI THERAPEUTICS PLC | AKARI THERAPEUTICS PLC |
| By: | */s/ Torsten Hombeck* |
| Name: | Torsten Hombeck |
| Title: | Chief Financial Officer |

---

cc: Win Rutherfurd (Greenberg Traurig, LLP)